Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.

Authors

Ana Laynez-Carnicero, MedStar Washington Hospital Center
Gabriel L. Sardi, MedStar Washington Hospital Center
Camille Hauville, MedStar Washington Hospital Center
Israel M. Barbash, MedStar Washington Hospital Center
Rajbabu Pakala, MedStar Washington Hospital Center
Rebecca Torguson, MedStar Washington Hospital CenterFollow
Zhenyi Xue, MedStar Washington Hospital CenterFollow
Lowell F. Satler, MedStar Washington Hospital CenterFollow
Augusto D. Pichard, MedStar Washington Hospital Center
Ron Waksman, MedStar Washington Hospital Center

Document Type

Journal Article

Publication Date

4-2012

Journal

Catheterization and Cardiovascular Interventions

Volume

Volume 81, Issue 5

Inclusive Pages

759-765

Keywords

Cardiovascular Agents--administration & dosage; Coronary Artery Disease--therapy; Diabetic Angiopathies--therapy; Drug-Eluting Stents; Paclitaxel--administration & dosage; Percutaneous Coronary Intervention--instrumentation; Sirolimus--analogs & derivatives

APA Citation

Laynez, A., Sardi, G., Hauville, C., Barbash, I. M., Pakala, R., Torguson, R., . . . Waksman, R. (2012). Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population. Catheterization and Cardiovascular Interventions, 81(5) 759-765.

Peer Reviewed

1